SPDR S&P Biotech ETF (NYSEARCA:XBI) Hits New 1-Year High – Time to Buy?

SPDR S&P Biotech ETF (NYSEARCA:XBI) reached a new 52-week high on Monday . The stock traded as high as $115.36 and last traded at $113.4070, with a volume of 14431001 shares changing hands. The stock had previously closed at $111.91.

SPDR S&P Biotech ETF Trading Up 0.3%

The business has a fifty day simple moving average of $105.00 and a two-hundred day simple moving average of $92.05. The company has a market cap of $6.99 billion, a PE ratio of 11.47 and a beta of 0.93.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of XBI. DHJJ Financial Advisors Ltd. acquired a new stake in SPDR S&P Biotech ETF during the second quarter worth about $25,000. Capital A Wealth Management LLC purchased a new stake in shares of SPDR S&P Biotech ETF in the 2nd quarter valued at approximately $26,000. Johnson Financial Group Inc. acquired a new stake in shares of SPDR S&P Biotech ETF during the 2nd quarter worth approximately $31,000. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the 2nd quarter valued at approximately $32,000. Finally, Davis Capital Management acquired a new position in SPDR S&P Biotech ETF in the third quarter valued at approximately $35,000.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.